Application of Antibody Engineering in the Development of Next Generation Antibody-Based Therapeutics

作者: Randall J. Brezski , Juan Carlos Almagro

DOI: 10.1007/978-1-4419-5955-3_4

关键词:

摘要: The evolution of therapeutic antibodies has encompassed multiple engineering efforts in the hope improving efficacy, safety, and duration effects antibody-based drugs. Advances protein technologies afforded investigators ability to overcome problems associated with introducing foreign into humans. These included antibody chimerization, humanization, more recent development human antibodies, all which reduced anti-drug immune responses. Additional have engineered variable regions that encode specificities a single molecular entity. Apart from optimizing antigen-binding capabilities reducing immunogenicity, many advances been made modulate an antibody’s interact cells serum components system. Manipulation glycosylation or amino acid sequence had significant impact on recruitment Fc-dependent effector functions. This chapter presents overview V region Fc modifications focuses tailor function relative intended need.

参考文章(153)
Bernard Scallon, Stephen McCarthy, Jennifer Radewonuk, Ann Cai, Michael Naso, T. Shantha Raju, Renold Capocasale, Quantitative in vivo comparisons of the Fcγ receptor-dependent agonist activities of different fucosylation variants of an immunoglobulin G antibody International Immunopharmacology. ,vol. 7, pp. 761- 772 ,(2007) , 10.1016/J.INTIMP.2007.01.014
C. F. Barbas, D. Hu, N. Dunlop, L. Sawyer, D. Cababa, R. M. Hendry, P. L. Nara, D. R. Burton, In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity Proceedings of the National Academy of Sciences of the United States of America. ,vol. 91, pp. 3809- 3813 ,(1994) , 10.1073/PNAS.91.9.3809
Jette Wypych, Ming Li, Amy Guo, Zhongqi Zhang, Theresa Martinez, Martin J. Allen, Szilan Fodor, Drew N. Kelner, Gregory C. Flynn, Yaoqing Diana Liu, Pavel V. Bondarenko, Margaret Speed Ricci, Thomas M. Dillon, Alain Balland, Human IgG2 Antibodies Display Disulfide-mediated Structural Isoforms Journal of Biological Chemistry. ,vol. 283, pp. 16194- 16205 ,(2008) , 10.1074/JBC.M709987200
Michael S Neuberger, Antibody diversification by somatic mutation: from Burnet onwards Immunology and Cell Biology. ,vol. 86, pp. 124- 132 ,(2008) , 10.1038/SJ.ICB.7100160
Guillaume Cartron, Laurent Dacheux, Gilles Salles, Philippe Solal-Celigny, Pierre Bardos, Philippe Colombat, Hervé Watier, Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene Blood. ,vol. 99, pp. 754- 758 ,(2002) , 10.1182/BLOOD.V99.3.754
Leonard G Presta, Molecular engineering and design of therapeutic antibodies Current Opinion in Immunology. ,vol. 20, pp. 460- 470 ,(2008) , 10.1016/J.COI.2008.06.012
Laurent Jespers, Oliver Schon, Kristoffer Famm, Greg Winter, Aggregation-resistant domain antibodies selected on phage by heat denaturation. Nature Biotechnology. ,vol. 22, pp. 1161- 1165 ,(2004) , 10.1038/NBT1000
LUCIENNE CHATENOUD, CHRISTIANE FERRAN, CHRISTOPHE LEGENDRE, ISABELLE THOUARD, SYLVIE MERITE, AIMÉE REUTER, YVONNE GEVAERT, HENRI KREIS, PAUL FRANCHIMONT, JEAN-FRANÇOIS BACH, In vivo cell activation following OKT3 administration. Systemic cytokine release and modulation by corticosteroids. Transplantation. ,vol. 49, pp. 697- 702 ,(1990) , 10.1097/00007890-199004000-00009
S. L. Sazinsky, R. G. Ott, N. W. Silver, B. Tidor, J. V. Ravetch, K. D. Wittrup, Aglycosylated immunoglobulin G1 variants productively engage activating Fc receptors Proceedings of the National Academy of Sciences of the United States of America. ,vol. 105, pp. 20167- 20172 ,(2008) , 10.1073/PNAS.0809257105